August 2015 August 2015
New Product - Sunvepra
Sunvepra (asunaprevir) is a selective inhibitor of the HCV nonstructural protein 3/4A (NS3/4A) protease. It is indicated in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults with compensated liver disease (including cirrhosis). Sunvepra is contraindicated in moderate to severe hepatic impairment (Child-Pugh B or C); decompensated liver disease; concomitant thioridazine, moderate to strong CYP3A inducers (including phenytoin, carbamazepine, oxcarbazepine, phenobarbitone, rifampicin, rifabutin, bosentan, dexamethasone, St John's wort, efavirenz, etravirine, nevirapine, modafinil), moderate to strong CYP3A inhibitors (including itraconazole, ketoconazole, posaconazole, voriconazole, fluconazole, clarithromycin, erythromycin, diltiazem, verapamil, atazanavir, ritonavir, darunavir/ ritonavir, fosamprenavir, indinavir, lopinavir/ ritonavir, saquinavir, cobicistat), OATP1B1 inhibitors (including cyclosporin, gemfibrozil); in combination with peginterferon and ribavirin, also males with pregnant female partners, women of childbearing potential (unless 2 forms of effective contraception used) including 6 months post-treatment of either partner, and pregnancy. Sunvepra is available as 100 mg capsules in packs of 56’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au